Lisanti Capital Growth LLC Invests $3.19 Million in Repligen Corporation $RGEN

Lisanti Capital Growth LLC bought a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 19,460 shares of the biotechnology company’s stock, valued at approximately $3,189,000.

A number of other hedge funds also recently made changes to their positions in the business. United Capital Financial Advisors LLC bought a new stake in shares of Repligen during the 3rd quarter worth $368,387,000. Holocene Advisors LP raised its stake in shares of Repligen by 47.0% during the 3rd quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after purchasing an additional 440,290 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in shares of Repligen during the 4th quarter worth $199,176,000. Alliancebernstein L.P. raised its stake in shares of Repligen by 21.8% during the 3rd quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock worth $147,595,000 after purchasing an additional 197,778 shares during the period. Finally, Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 10.6% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after purchasing an additional 101,062 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Trading Up 1.5%

Shares of Repligen stock opened at $115.06 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The stock has a market capitalization of $6.49 billion, a P/E ratio of 127.85, a P/E/G ratio of 2.22 and a beta of 1.09. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The stock’s 50-day simple moving average is $117.74 and its 200 day simple moving average is $140.77.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts anticipate that Repligen Corporation will post 1.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th. UBS Group lowered their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Barclays boosted their price objective on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Canaccord Genuity Group lowered their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $166.15.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.